SanBio has been granted a patent for a method and culture medium to induce polarization in multipotent stem cells. The method involves using specific agents and ligands to produce therapeutic cells and extracellular vesicles. GlobalData’s report on SanBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on SanBio, NSAID cancer drugs was a key innovation area identified from patents. SanBio's grant share as of May 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Method for inducing polarization in mesenchymal stem cells
A recently granted patent (Publication Number: US11946072B2) discloses a method for producing an immunologically polarized mesenchymal stem cell population from an unstimulated mesenchymal stem cell population. The method involves contacting the unstimulated cells with a culture medium containing a Toll-like receptor 3 (TLR3) ligand and an agent such as acetylcholine, norepinephrine, epinephrine, serotonin, or melatonin, leading to the induction of CXCL9 expression in the resulting immunologically polarized mesenchymal stem cell population. The use of specific TLR3 ligands like poly (I:C) or poly (A:U), along with the inclusion of erythropoietin in the culture medium, further enhances the polarization process.
Additionally, the method includes conducting the culture under hypoxic conditions, with varying oxygen levels ranging from less than 8% to as low as 0.5%. The concentration of the agent, such as acetylcholine, in the culture medium plays a crucial role, with specified ranges from 1 nanomolar to 100 micromolar. The duration of contact between the unstimulated mesenchymal stem cell population and the culture medium is also defined, emphasizing the importance of timing in the polarization process. These specific parameters outlined in the patent aim to provide a reproducible method for generating immunologically polarized mesenchymal stem cells, which could have significant implications in various therapeutic applications.
To know more about GlobalData’s detailed insights on SanBio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
